Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients

Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hospitalized patients, contributing to their morbidity and mortality. These organisms may still keep their sensitivity to coli...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Mohamed Amin [verfasserIn] Alaa Rashad [verfasserIn] Assem Fouad [verfasserIn] Amal Abdel Azeem [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2013

Schlagwörter:	Colistin Polymyxin Inhaled Pneumonia Gram negative Drug resistant

Übergeordnetes Werk:	In: Egyptian Journal of Chest Disease and Tuberculosis - Wolters Kluwer Medknow Publications, 2016, 62(2013), 3, Seite 447-451
Übergeordnetes Werk:	volume:62 ; year:2013 ; number:3 ; pages:447-451

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1016/j.ejcdt.2013.05.012

Katalog-ID:	DOAJ073520349

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ073520349
003	DE-627
005	20230309115443.0
007	cr uuu---uuuuu
008	230228s2013 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.ejcdt.2013.05.012 \|2 doi
035			\|a (DE-627)DOAJ073520349
035			\|a (DE-599)DOAJcc6d59cc7e124c359d0fc12a7bad5051
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC705-779
100	0		\|a Mohamed Amin \|e verfasserin \|4 aut
245	1	0	\|a Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients
264		1	\|c 2013
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hospitalized patients, contributing to their morbidity and mortality. These organisms may still keep their sensitivity to colistin and allowed its use for these selective therapeutic indications. Objectives: The aim of the present study is to evaluate and compare the effectiveness and safety of both combined intravenous (i.v.) colistin with aerosolized colistin versus i.v. colistin alone in nosocomial pneumonia due to MDR G-ve pathogens in critically ill patients. Methods: 40 Patients were hospitalized in ICU due to different etiologies. These patients experienced nosocomial pneumonia. The pathogenic organisms were G-ve MDR bacilli and only susceptible to colistin. The first group received both i.v. colistin with aerosolized colistin versus (vs.) the second group who received i.v. colistin alone. Results: Mortality was less in patients who received i.v. plus inhaled colistin. Conclusion: Colistin is a reasonable safe last-line therapeutic alternative for pneumonia due to MDR G-ve pathogens. Aerosolized colistin may be considered as a useful adjunctive to i.v. colistin.
650		4	\|a Colistin
650		4	\|a Polymyxin
650		4	\|a Inhaled
650		4	\|a Pneumonia
650		4	\|a Gram negative
650		4	\|a Drug resistant
653		0	\|a Diseases of the respiratory system
700	0		\|a Alaa Rashad \|e verfasserin \|4 aut
700	0		\|a Assem Fouad \|e verfasserin \|4 aut
700	0		\|a Amal Abdel Azeem \|e verfasserin \|4 aut
773	0	8	\|i In \|t Egyptian Journal of Chest Disease and Tuberculosis \|d Wolters Kluwer Medknow Publications, 2016 \|g 62(2013), 3, Seite 447-451 \|w (DE-627)820688878 \|w (DE-600)2814778-9 \|x 20909950 \|7 nnns
773	1	8	\|g volume:62 \|g year:2013 \|g number:3 \|g pages:447-451
856	4	0	\|u https://doi.org/10.1016/j.ejcdt.2013.05.012 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/cc6d59cc7e124c359d0fc12a7bad5051 \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S0422763813001064 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0422-7638 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 62 \|j 2013 \|e 3 \|h 447-451

Indexfelder

author_variant	m a ma a r ar a f af a a a aaa
matchkey_str	article:20909950:2013----::emrigfoitnotetetfoooilnuoideormeaieutdurssata
hierarchy_sort_str	2013
callnumber-subject-code	RC
publishDate	2013
allfields	10.1016/j.ejcdt.2013.05.012 doi (DE-627)DOAJ073520349 (DE-599)DOAJcc6d59cc7e124c359d0fc12a7bad5051 DE-627 ger DE-627 rakwb eng RC705-779 Mohamed Amin verfasserin aut Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hospitalized patients, contributing to their morbidity and mortality. These organisms may still keep their sensitivity to colistin and allowed its use for these selective therapeutic indications. Objectives: The aim of the present study is to evaluate and compare the effectiveness and safety of both combined intravenous (i.v.) colistin with aerosolized colistin versus i.v. colistin alone in nosocomial pneumonia due to MDR G-ve pathogens in critically ill patients. Methods: 40 Patients were hospitalized in ICU due to different etiologies. These patients experienced nosocomial pneumonia. The pathogenic organisms were G-ve MDR bacilli and only susceptible to colistin. The first group received both i.v. colistin with aerosolized colistin versus (vs.) the second group who received i.v. colistin alone. Results: Mortality was less in patients who received i.v. plus inhaled colistin. Conclusion: Colistin is a reasonable safe last-line therapeutic alternative for pneumonia due to MDR G-ve pathogens. Aerosolized colistin may be considered as a useful adjunctive to i.v. colistin. Colistin Polymyxin Inhaled Pneumonia Gram negative Drug resistant Diseases of the respiratory system Alaa Rashad verfasserin aut Assem Fouad verfasserin aut Amal Abdel Azeem verfasserin aut In Egyptian Journal of Chest Disease and Tuberculosis Wolters Kluwer Medknow Publications, 2016 62(2013), 3, Seite 447-451 (DE-627)820688878 (DE-600)2814778-9 20909950 nnns volume:62 year:2013 number:3 pages:447-451 https://doi.org/10.1016/j.ejcdt.2013.05.012 kostenfrei https://doaj.org/article/cc6d59cc7e124c359d0fc12a7bad5051 kostenfrei http://www.sciencedirect.com/science/article/pii/S0422763813001064 kostenfrei https://doaj.org/toc/0422-7638 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 62 2013 3 447-451
spelling	10.1016/j.ejcdt.2013.05.012 doi (DE-627)DOAJ073520349 (DE-599)DOAJcc6d59cc7e124c359d0fc12a7bad5051 DE-627 ger DE-627 rakwb eng RC705-779 Mohamed Amin verfasserin aut Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hospitalized patients, contributing to their morbidity and mortality. These organisms may still keep their sensitivity to colistin and allowed its use for these selective therapeutic indications. Objectives: The aim of the present study is to evaluate and compare the effectiveness and safety of both combined intravenous (i.v.) colistin with aerosolized colistin versus i.v. colistin alone in nosocomial pneumonia due to MDR G-ve pathogens in critically ill patients. Methods: 40 Patients were hospitalized in ICU due to different etiologies. These patients experienced nosocomial pneumonia. The pathogenic organisms were G-ve MDR bacilli and only susceptible to colistin. The first group received both i.v. colistin with aerosolized colistin versus (vs.) the second group who received i.v. colistin alone. Results: Mortality was less in patients who received i.v. plus inhaled colistin. Conclusion: Colistin is a reasonable safe last-line therapeutic alternative for pneumonia due to MDR G-ve pathogens. Aerosolized colistin may be considered as a useful adjunctive to i.v. colistin. Colistin Polymyxin Inhaled Pneumonia Gram negative Drug resistant Diseases of the respiratory system Alaa Rashad verfasserin aut Assem Fouad verfasserin aut Amal Abdel Azeem verfasserin aut In Egyptian Journal of Chest Disease and Tuberculosis Wolters Kluwer Medknow Publications, 2016 62(2013), 3, Seite 447-451 (DE-627)820688878 (DE-600)2814778-9 20909950 nnns volume:62 year:2013 number:3 pages:447-451 https://doi.org/10.1016/j.ejcdt.2013.05.012 kostenfrei https://doaj.org/article/cc6d59cc7e124c359d0fc12a7bad5051 kostenfrei http://www.sciencedirect.com/science/article/pii/S0422763813001064 kostenfrei https://doaj.org/toc/0422-7638 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 62 2013 3 447-451
allfields_unstemmed	10.1016/j.ejcdt.2013.05.012 doi (DE-627)DOAJ073520349 (DE-599)DOAJcc6d59cc7e124c359d0fc12a7bad5051 DE-627 ger DE-627 rakwb eng RC705-779 Mohamed Amin verfasserin aut Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hospitalized patients, contributing to their morbidity and mortality. These organisms may still keep their sensitivity to colistin and allowed its use for these selective therapeutic indications. Objectives: The aim of the present study is to evaluate and compare the effectiveness and safety of both combined intravenous (i.v.) colistin with aerosolized colistin versus i.v. colistin alone in nosocomial pneumonia due to MDR G-ve pathogens in critically ill patients. Methods: 40 Patients were hospitalized in ICU due to different etiologies. These patients experienced nosocomial pneumonia. The pathogenic organisms were G-ve MDR bacilli and only susceptible to colistin. The first group received both i.v. colistin with aerosolized colistin versus (vs.) the second group who received i.v. colistin alone. Results: Mortality was less in patients who received i.v. plus inhaled colistin. Conclusion: Colistin is a reasonable safe last-line therapeutic alternative for pneumonia due to MDR G-ve pathogens. Aerosolized colistin may be considered as a useful adjunctive to i.v. colistin. Colistin Polymyxin Inhaled Pneumonia Gram negative Drug resistant Diseases of the respiratory system Alaa Rashad verfasserin aut Assem Fouad verfasserin aut Amal Abdel Azeem verfasserin aut In Egyptian Journal of Chest Disease and Tuberculosis Wolters Kluwer Medknow Publications, 2016 62(2013), 3, Seite 447-451 (DE-627)820688878 (DE-600)2814778-9 20909950 nnns volume:62 year:2013 number:3 pages:447-451 https://doi.org/10.1016/j.ejcdt.2013.05.012 kostenfrei https://doaj.org/article/cc6d59cc7e124c359d0fc12a7bad5051 kostenfrei http://www.sciencedirect.com/science/article/pii/S0422763813001064 kostenfrei https://doaj.org/toc/0422-7638 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 62 2013 3 447-451
allfieldsGer	10.1016/j.ejcdt.2013.05.012 doi (DE-627)DOAJ073520349 (DE-599)DOAJcc6d59cc7e124c359d0fc12a7bad5051 DE-627 ger DE-627 rakwb eng RC705-779 Mohamed Amin verfasserin aut Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hospitalized patients, contributing to their morbidity and mortality. These organisms may still keep their sensitivity to colistin and allowed its use for these selective therapeutic indications. Objectives: The aim of the present study is to evaluate and compare the effectiveness and safety of both combined intravenous (i.v.) colistin with aerosolized colistin versus i.v. colistin alone in nosocomial pneumonia due to MDR G-ve pathogens in critically ill patients. Methods: 40 Patients were hospitalized in ICU due to different etiologies. These patients experienced nosocomial pneumonia. The pathogenic organisms were G-ve MDR bacilli and only susceptible to colistin. The first group received both i.v. colistin with aerosolized colistin versus (vs.) the second group who received i.v. colistin alone. Results: Mortality was less in patients who received i.v. plus inhaled colistin. Conclusion: Colistin is a reasonable safe last-line therapeutic alternative for pneumonia due to MDR G-ve pathogens. Aerosolized colistin may be considered as a useful adjunctive to i.v. colistin. Colistin Polymyxin Inhaled Pneumonia Gram negative Drug resistant Diseases of the respiratory system Alaa Rashad verfasserin aut Assem Fouad verfasserin aut Amal Abdel Azeem verfasserin aut In Egyptian Journal of Chest Disease and Tuberculosis Wolters Kluwer Medknow Publications, 2016 62(2013), 3, Seite 447-451 (DE-627)820688878 (DE-600)2814778-9 20909950 nnns volume:62 year:2013 number:3 pages:447-451 https://doi.org/10.1016/j.ejcdt.2013.05.012 kostenfrei https://doaj.org/article/cc6d59cc7e124c359d0fc12a7bad5051 kostenfrei http://www.sciencedirect.com/science/article/pii/S0422763813001064 kostenfrei https://doaj.org/toc/0422-7638 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 62 2013 3 447-451
allfieldsSound	10.1016/j.ejcdt.2013.05.012 doi (DE-627)DOAJ073520349 (DE-599)DOAJcc6d59cc7e124c359d0fc12a7bad5051 DE-627 ger DE-627 rakwb eng RC705-779 Mohamed Amin verfasserin aut Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hospitalized patients, contributing to their morbidity and mortality. These organisms may still keep their sensitivity to colistin and allowed its use for these selective therapeutic indications. Objectives: The aim of the present study is to evaluate and compare the effectiveness and safety of both combined intravenous (i.v.) colistin with aerosolized colistin versus i.v. colistin alone in nosocomial pneumonia due to MDR G-ve pathogens in critically ill patients. Methods: 40 Patients were hospitalized in ICU due to different etiologies. These patients experienced nosocomial pneumonia. The pathogenic organisms were G-ve MDR bacilli and only susceptible to colistin. The first group received both i.v. colistin with aerosolized colistin versus (vs.) the second group who received i.v. colistin alone. Results: Mortality was less in patients who received i.v. plus inhaled colistin. Conclusion: Colistin is a reasonable safe last-line therapeutic alternative for pneumonia due to MDR G-ve pathogens. Aerosolized colistin may be considered as a useful adjunctive to i.v. colistin. Colistin Polymyxin Inhaled Pneumonia Gram negative Drug resistant Diseases of the respiratory system Alaa Rashad verfasserin aut Assem Fouad verfasserin aut Amal Abdel Azeem verfasserin aut In Egyptian Journal of Chest Disease and Tuberculosis Wolters Kluwer Medknow Publications, 2016 62(2013), 3, Seite 447-451 (DE-627)820688878 (DE-600)2814778-9 20909950 nnns volume:62 year:2013 number:3 pages:447-451 https://doi.org/10.1016/j.ejcdt.2013.05.012 kostenfrei https://doaj.org/article/cc6d59cc7e124c359d0fc12a7bad5051 kostenfrei http://www.sciencedirect.com/science/article/pii/S0422763813001064 kostenfrei https://doaj.org/toc/0422-7638 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 62 2013 3 447-451
language	English
source	In Egyptian Journal of Chest Disease and Tuberculosis 62(2013), 3, Seite 447-451 volume:62 year:2013 number:3 pages:447-451
sourceStr	In Egyptian Journal of Chest Disease and Tuberculosis 62(2013), 3, Seite 447-451 volume:62 year:2013 number:3 pages:447-451
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Colistin Polymyxin Inhaled Pneumonia Gram negative Drug resistant Diseases of the respiratory system
isfreeaccess_bool	true
container_title	Egyptian Journal of Chest Disease and Tuberculosis
authorswithroles_txt_mv	Mohamed Amin @@aut@@ Alaa Rashad @@aut@@ Assem Fouad @@aut@@ Amal Abdel Azeem @@aut@@
publishDateDaySort_date	2013-01-01T00:00:00Z
hierarchy_top_id	820688878
id	DOAJ073520349
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ073520349</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309115443.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejcdt.2013.05.012</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ073520349</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcc6d59cc7e124c359d0fc12a7bad5051</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC705-779</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Mohamed Amin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hospitalized patients, contributing to their morbidity and mortality. These organisms may still keep their sensitivity to colistin and allowed its use for these selective therapeutic indications. Objectives: The aim of the present study is to evaluate and compare the effectiveness and safety of both combined intravenous (i.v.) colistin with aerosolized colistin versus i.v. colistin alone in nosocomial pneumonia due to MDR G-ve pathogens in critically ill patients. Methods: 40 Patients were hospitalized in ICU due to different etiologies. These patients experienced nosocomial pneumonia. The pathogenic organisms were G-ve MDR bacilli and only susceptible to colistin. The first group received both i.v. colistin with aerosolized colistin versus (vs.) the second group who received i.v. colistin alone. Results: Mortality was less in patients who received i.v. plus inhaled colistin. Conclusion: Colistin is a reasonable safe last-line therapeutic alternative for pneumonia due to MDR G-ve pathogens. Aerosolized colistin may be considered as a useful adjunctive to i.v. colistin.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Colistin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Polymyxin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inhaled</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pneumonia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gram negative</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug resistant</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the respiratory system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alaa Rashad</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Assem Fouad</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Amal Abdel Azeem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Egyptian Journal of Chest Disease and Tuberculosis</subfield><subfield code="d">Wolters Kluwer Medknow Publications, 2016</subfield><subfield code="g">62(2013), 3, Seite 447-451</subfield><subfield code="w">(DE-627)820688878</subfield><subfield code="w">(DE-600)2814778-9</subfield><subfield code="x">20909950</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:62</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:447-451</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejcdt.2013.05.012</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cc6d59cc7e124c359d0fc12a7bad5051</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S0422763813001064</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0422-7638</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">62</subfield><subfield code="j">2013</subfield><subfield code="e">3</subfield><subfield code="h">447-451</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Mohamed Amin
spellingShingle	Mohamed Amin misc RC705-779 misc Colistin misc Polymyxin misc Inhaled misc Pneumonia misc Gram negative misc Drug resistant misc Diseases of the respiratory system Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients
authorStr	Mohamed Amin
ppnlink_with_tag_str_mv	@@773@@(DE-627)820688878
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC705-779
illustrated	Not Illustrated
issn	20909950
topic_title	RC705-779 Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients Colistin Polymyxin Inhaled Pneumonia Gram negative Drug resistant
topic	misc RC705-779 misc Colistin misc Polymyxin misc Inhaled misc Pneumonia misc Gram negative misc Drug resistant misc Diseases of the respiratory system
topic_unstemmed	misc RC705-779 misc Colistin misc Polymyxin misc Inhaled misc Pneumonia misc Gram negative misc Drug resistant misc Diseases of the respiratory system
topic_browse	misc RC705-779 misc Colistin misc Polymyxin misc Inhaled misc Pneumonia misc Gram negative misc Drug resistant misc Diseases of the respiratory system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Egyptian Journal of Chest Disease and Tuberculosis
hierarchy_parent_id	820688878
hierarchy_top_title	Egyptian Journal of Chest Disease and Tuberculosis
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)820688878 (DE-600)2814778-9
title	Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients
ctrlnum	(DE-627)DOAJ073520349 (DE-599)DOAJcc6d59cc7e124c359d0fc12a7bad5051
title_full	Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients
author_sort	Mohamed Amin
journal	Egyptian Journal of Chest Disease and Tuberculosis
journalStr	Egyptian Journal of Chest Disease and Tuberculosis
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2013
contenttype_str_mv	txt
container_start_page	447
author_browse	Mohamed Amin Alaa Rashad Assem Fouad Amal Abdel Azeem
container_volume	62
class	RC705-779
format_se	Elektronische Aufsätze
author-letter	Mohamed Amin
doi_str_mv	10.1016/j.ejcdt.2013.05.012
author2-role	verfasserin
title_sort	re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients
callnumber	RC705-779
title_auth	Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients
abstract	Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hospitalized patients, contributing to their morbidity and mortality. These organisms may still keep their sensitivity to colistin and allowed its use for these selective therapeutic indications. Objectives: The aim of the present study is to evaluate and compare the effectiveness and safety of both combined intravenous (i.v.) colistin with aerosolized colistin versus i.v. colistin alone in nosocomial pneumonia due to MDR G-ve pathogens in critically ill patients. Methods: 40 Patients were hospitalized in ICU due to different etiologies. These patients experienced nosocomial pneumonia. The pathogenic organisms were G-ve MDR bacilli and only susceptible to colistin. The first group received both i.v. colistin with aerosolized colistin versus (vs.) the second group who received i.v. colistin alone. Results: Mortality was less in patients who received i.v. plus inhaled colistin. Conclusion: Colistin is a reasonable safe last-line therapeutic alternative for pneumonia due to MDR G-ve pathogens. Aerosolized colistin may be considered as a useful adjunctive to i.v. colistin.
abstractGer	Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hospitalized patients, contributing to their morbidity and mortality. These organisms may still keep their sensitivity to colistin and allowed its use for these selective therapeutic indications. Objectives: The aim of the present study is to evaluate and compare the effectiveness and safety of both combined intravenous (i.v.) colistin with aerosolized colistin versus i.v. colistin alone in nosocomial pneumonia due to MDR G-ve pathogens in critically ill patients. Methods: 40 Patients were hospitalized in ICU due to different etiologies. These patients experienced nosocomial pneumonia. The pathogenic organisms were G-ve MDR bacilli and only susceptible to colistin. The first group received both i.v. colistin with aerosolized colistin versus (vs.) the second group who received i.v. colistin alone. Results: Mortality was less in patients who received i.v. plus inhaled colistin. Conclusion: Colistin is a reasonable safe last-line therapeutic alternative for pneumonia due to MDR G-ve pathogens. Aerosolized colistin may be considered as a useful adjunctive to i.v. colistin.
abstract_unstemmed	Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hospitalized patients, contributing to their morbidity and mortality. These organisms may still keep their sensitivity to colistin and allowed its use for these selective therapeutic indications. Objectives: The aim of the present study is to evaluate and compare the effectiveness and safety of both combined intravenous (i.v.) colistin with aerosolized colistin versus i.v. colistin alone in nosocomial pneumonia due to MDR G-ve pathogens in critically ill patients. Methods: 40 Patients were hospitalized in ICU due to different etiologies. These patients experienced nosocomial pneumonia. The pathogenic organisms were G-ve MDR bacilli and only susceptible to colistin. The first group received both i.v. colistin with aerosolized colistin versus (vs.) the second group who received i.v. colistin alone. Results: Mortality was less in patients who received i.v. plus inhaled colistin. Conclusion: Colistin is a reasonable safe last-line therapeutic alternative for pneumonia due to MDR G-ve pathogens. Aerosolized colistin may be considered as a useful adjunctive to i.v. colistin.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	3
title_short	Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients
url	https://doi.org/10.1016/j.ejcdt.2013.05.012 https://doaj.org/article/cc6d59cc7e124c359d0fc12a7bad5051 http://www.sciencedirect.com/science/article/pii/S0422763813001064 https://doaj.org/toc/0422-7638
remote_bool	true
author2	Alaa Rashad Assem Fouad Amal Abdel Azeem
author2Str	Alaa Rashad Assem Fouad Amal Abdel Azeem
ppnlink	820688878
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1016/j.ejcdt.2013.05.012
callnumber-a	RC705-779
up_date	2024-07-03T18:08:49.655Z
_version_	1803582313235218432
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ073520349</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309115443.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejcdt.2013.05.012</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ073520349</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcc6d59cc7e124c359d0fc12a7bad5051</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC705-779</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Mohamed Amin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hospitalized patients, contributing to their morbidity and mortality. These organisms may still keep their sensitivity to colistin and allowed its use for these selective therapeutic indications. Objectives: The aim of the present study is to evaluate and compare the effectiveness and safety of both combined intravenous (i.v.) colistin with aerosolized colistin versus i.v. colistin alone in nosocomial pneumonia due to MDR G-ve pathogens in critically ill patients. Methods: 40 Patients were hospitalized in ICU due to different etiologies. These patients experienced nosocomial pneumonia. The pathogenic organisms were G-ve MDR bacilli and only susceptible to colistin. The first group received both i.v. colistin with aerosolized colistin versus (vs.) the second group who received i.v. colistin alone. Results: Mortality was less in patients who received i.v. plus inhaled colistin. Conclusion: Colistin is a reasonable safe last-line therapeutic alternative for pneumonia due to MDR G-ve pathogens. Aerosolized colistin may be considered as a useful adjunctive to i.v. colistin.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Colistin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Polymyxin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inhaled</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pneumonia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gram negative</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug resistant</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the respiratory system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alaa Rashad</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Assem Fouad</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Amal Abdel Azeem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Egyptian Journal of Chest Disease and Tuberculosis</subfield><subfield code="d">Wolters Kluwer Medknow Publications, 2016</subfield><subfield code="g">62(2013), 3, Seite 447-451</subfield><subfield code="w">(DE-627)820688878</subfield><subfield code="w">(DE-600)2814778-9</subfield><subfield code="x">20909950</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:62</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:447-451</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejcdt.2013.05.012</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cc6d59cc7e124c359d0fc12a7bad5051</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S0422763813001064</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0422-7638</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">62</subfield><subfield code="j">2013</subfield><subfield code="e">3</subfield><subfield code="h">447-451</subfield></datafield></record></collection>
score	7.4010954

Nicht das Richtige dabei?

Schreiben Sie uns!

Re-emerging of colistin for treatment of nosocomial pneumonia due to gram negative multi-drug resistant pathogens in critically ill patients

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?